Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization

To evaluate the potential of drug-eluting bead (DEB)-transcatheter arterial chemoembolization (TACE) as a treatment option for patients with refractory to conventional lipiodol-based TACE (c-TACE) especially with decreased liver function. We retrospectively evaluated the treatment results of DEB-TAC...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatocellular carcinoma 2020-10, Vol.7, p.181-189
Main Authors: Kobayashi, Saito, Tajiri, Kazuto, Murayama, Aiko, Entani, Toshiki, Futsukaichi, Yuka, Nagata, Kohei, Takahashi, Kosuke, Yasuda, Ichiro
Format: Article
Language:English
Subjects:
Antitumor activity
Cancer therapies
Chemoembolization
Drug delivery
drug-eluting bead
Hepatocellular carcinoma
Liver cancer
Medical prognosis
microsphere
Original Research
Patients
post-embolization syndrome
tace-refractory
Tumors
tyrosine kinase inhibitor
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the potential of drug-eluting bead (DEB)-transcatheter arterial chemoembolization (TACE) as a treatment option for patients with refractory to conventional lipiodol-based TACE (c-TACE) especially with decreased liver function. We retrospectively evaluated the treatment results of DEB-TACE for 89 HCC nodules in 27 patients with c-TACE refractory according to liver function. Although overall survival was significantly better in Child-Pugh A patients than in Child-Pugh B patients (median survival time, MST: 561 vs 347 days, =0.031), progression-free survival was almost similar in both patients between Child-Pugh A and B (MST: 79 vs 87 days, =0.534). Regarding antitumor response, the objective response rate (ORR) and disease-control rate (DCR) were 5.3/12.5% and 52.7/87.5% in Child-Pugh A/B, respectively. In each 89 HCC nodules, ORR and DCR were almost similar between Child-Pugh A and B (ORR, 20.3 vs 13.3%; DCR, 77.0 vs 73.3%, respectively). Adverse events of DEB-TACE were well-tolerated, and liver function was reserved during DEB-TACE procedures. DEB-TACE could be a therapeutic option for advanced HCC patients with c-TACE refractory and decreased liver function.
ISSN:2253-5969
2253-5969
DOI:10.2147/jhc.s273929